Search results for "Cost-benefit analysi"

showing 10 items of 148 documents

Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain).

2011

Background: Heptavalent pneumococcal conjugate vaccine (PCV-7) was licensed to provide immunity against pneumococcal disease caused by seven serotypes of S. pneumoniae. Thirteen-valent pneumococcal conjugate vaccine (PCV-13) includes 6 additional serotypes for preventing invasive pneumococcal disease. Objective: The objective of this study was to estimate the potential health benefits, costs, and cost-effectiveness of vaccination with PCV-13 in the Community of Valencia and to generate valuable information for policy makers at regional and country levels. Methods: A decision tree was designed to determine the health and economic outcomes in hypothetical cohorts of vaccinated and unvaccinate…

AdultMalePediatricsmedicine.medical_specialtyAdolescentCost effectivenessPharmacoeconomic assessmentCost-Benefit AnalysisPneumococcal conjugate vaccinePneumococcal InfectionsHerd immunityPneumococcal VaccinesIndirect costsYoung AdultEnvironmental healthmedicineHeptavalent Pneumococcal Conjugate VaccineHumansChildAgedAged 80 and overGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryPneumococcal conjugate vaccineVaccinationPublic Health Environmental and Occupational HealthInfant NewbornInfantMiddle AgedQuality-adjusted life yearVaccinationInfectious DiseasesSpainChild PreschoolCohortMolecular MedicineCost-effectivenessFemalebusinessmedicine.drugVaccine
researchProduct

Reslizumab as add-on therapy in patients with refractory asthma

2020

### Key messages #### What is the key question? #### What is the bottom line? #### Why read on? Asthma is a common disease, affecting an estimated 334 million people worldwide, with considerable impact on quality of life and high associated costs.1–3 Asthma severity is assessed retrospectively from the level of treatment required to control symptoms and exacerbations. Approximately 5%–10% of patients with asthma are believed to suffer from severe disease.4 Patients with severe asthma typically require ongoing maintenance therapy with high-dose inhaled corticosteroid (ICS)/long-acting beta-agonist (LABA).2 Furthermore, systemic corticosteroids (SCS) are often required for potentially life-th…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentmedicine.drug_classCost-Benefit Analysislcsh:MedicineInflammationAntibodies Monoclonal HumanizedYoung Adult03 medical and health sciences0302 clinical medicineReslizumabQuality of lifeMaintenance therapyAdrenal Cortex HormonesInternal medicinemedicineHumans1506Anti-Asthmatic Agents030212 general & internal medicineChildAdrenergic beta-2 Receptor AgonistsPulmonary EosinophiliaAgedAsthmalcsh:RC705-779business.industrylcsh:Rlcsh:Diseases of the respiratory systemMiddle AgedEosinophilmedicine.diseaseAsthmarespiratory tract diseasesTreatment Outcomemedicine.anatomical_structure030228 respiratory systempulmonary eosinophiliaRegression AnalysisCorticosteroidFemalemedicine.symptombusinessmedicine.drugBMJ Open Respiratory Research
researchProduct

Ethical assessment of hepatitis C virus treatment: The lesson from first generation protease inhibitors

2015

Abstract Since chronic hepatitis C has mostly become curable, issues concerning choice and allocation of treatment are of major concern. We assessed the foremost ethical issues in hepatitis C virus therapy with 1st generation protease inhibitors using the personalist ethical framework within the health technology assessment methodology. Our aim was to identify values at stake/in conflict and to support both the physicians’ choices in hepatitis C therapy and social (macro-) allocation decision-making. The ethical assessment indicates that: (1) safety/effectiveness profile of treatment is guaranteed if its use is restricted to the patients subgroups who may benefit from it; (2) patients shoul…

AdultMalehepatitis C virusmedicine.medical_specialtyPathologyCost-Benefit AnalysisHepatitis C virusDecision MakingProtease InhibitoreducationAlternative medicineHepacivirusDirect-acting antiviralmedicine.disease_causeAntiviral AgentsSettore MED/02 - Storia Della MedicinaResource (project management)medicineHumansProtease InhibitorsEthics MedicalEthichealth technology assessmentCost-Benefit AnalysiDeferralIntensive care medicineEthical frameworkdirect-acting antiviralsAgedAntiviral AgentSettore MED/12 - GastroenterologiaHepaciviruHepatologybusiness.industryGastroenterologyHealth technologyHepatitis CMiddle AgedSettore MED/43 - MEDICINA LEGALEmedicine.diseaseHepatitis CethicsFirst generationDrug Therapy CombinationFemaleHepatitis C virubusinessHuman
researchProduct

Telemonitoring of Crohn's Disease and Ulcerative Colitis (TECCU): Cost-Effectiveness Analysis.

2019

Background Although electronic health interventions are considered safe and efficient, evidence regarding the cost-effectiveness of telemonitoring in inflammatory bowel disease is lacking. Objective We aimed to evaluate the cost-effectiveness and cost-utility of the Telemonitorización de la Enfermedad de Crohn y Colitis Ulcerosa (Telemonitoring of Crohn’s Disease and Ulcerative Colitis [TECCU]) Web platform (G_TECCU intervention group) for telemonitoring complex inflammatory bowel disease, compared with standard care (G_control) and nurse-assisted telephone care (G_NT intervention group). Methods We analyzed cost-effectiveness from a societal perspective by comparing the 3 follow-up method…

AdultMalemedicine.medical_specialty020205 medical informaticsCost effectivenessCost-Benefit AnalysisPsychological interventionHealth Informatics02 engineering and technologylcsh:Computer applications to medicine. Medical informaticsInflammatory bowel diseaseinflammatory bowel diseaseslaw.invention03 medical and health sciencesYoung Adult0302 clinical medicineRandomized controlled triallawInternal medicineHealth care0202 electrical engineering electronic engineering information engineeringmedicineHumanscost-effectivenessCrohn's diseaseOriginal Papercolitis ulcerativebusiness.industrylcsh:Public aspects of medicineCrohn diseaselcsh:RA1-1270Cost-effectiveness analysisMiddle Agedmedicine.diseaseUlcerative colitisTelemedicinelcsh:R858-859.7030211 gastroenterology & hepatologyFemaleeHealthbusinessJournal of medical Internet research
researchProduct

Efficacy and cost-effectiveness of a blended cognitive behavioral therapy for depression in Spanish primary health care:Study protocol for a randomis…

2018

Background: Data from primary health care in Spain show a high prevalence of the major depressive disorder. Blended treatment (combination of face-to-face and online components) seems to be a very promising tool for the optimization and dissemination of psychological treatments in a cost-effective form. Although there is growing data that confirm the advantages of blended therapies, few studies have analyzed their application in regular clinical practice. The objective of the present paper is to describe the protocol for a clinical study aimed at exploring the clinical and cost-effectiveness of a blended cognitive behavioral therapy (b-CBT) for depression, compared to treatment as usual (TA…

AdultMalemedicine.medical_specialtyAdolescentlcsh:RC435-571Cost effectivenessmedicine.medical_treatmentCost-Benefit AnalysisInternet-based treatmentEquivalence Trials as TopicRandomised non-inferiority trial03 medical and health sciencesStudy ProtocolYoung Adult0302 clinical medicinePatient satisfactionQuality of life (healthcare)SDG 3 - Good Health and Well-beinglcsh:PsychiatrymedicineHumans030212 general & internal medicineYoung adultBlended treatmentDepression (differential diagnoses)Randomized Controlled Trials as TopicPrimary health careCognitive Behavioral TherapyPrimary Health Carebusiness.industryDepressionRepeated measures designProfessional-Patient Relationsmedicine.disease3. Good health030227 psychiatryCognitive behavioral therapyCognitive behavioral therapyPsychiatry and Mental healthTreatment OutcomePatient SatisfactionSpainPhysical therapyQuality of LifeMajor depressive disorder/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemalebusiness
researchProduct

Refined atrial fibrillation screening and cost-effectiveness in the German population

2021

ObjectiveLittle is known on optimal screening population for detecting new atrial fibrillation (AF) in the community. We describe characteristics and estimate cost-effectiveness for a single timepoint electrocardiographic screening.MethodsWe performed a 12-lead ECG in the German population-based Gutenberg Health Study between 2007 and 2012 (n=15 010), mean age 55±11 years, 51% men and collected more than 120 clinical and biomarker variables, including N-terminal pro B-type natriuretic peptide (Nt-proBNP), risk factors, disease symptoms and echocardiographic variables.ResultsOf 15 010 individuals, 466 (3.1%) had AF. New AF was found in 32 individuals, 0.2% of the total sample, 0.5% of indivi…

AdultMalemedicine.medical_specialtyCost effectivenessCost-Benefit AnalysisPopulation030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineAtrial FibrillationNatriuretic Peptide BrainEpidemiologyHumansMedicine030212 general & internal medicineRisk factoreducationStrokeAgedHeart Failureeducation.field_of_studybusiness.industryAtrial fibrillationMiddle Agedmedicine.diseasePeptide Fragments3. Good healthStrokeHeart failureBiomarker (medicine)FemaleCardiology and Cardiovascular MedicinebusinessBiomarkersHeart
researchProduct

A controlled treatment study of somatoform disorders including analysis of healthcare utilization and cost-effectiveness.

2003

Abstract Objective: The purpose of this prospective study was to evaluate the effects of cognitive-behavioral treatment (CBT) on mental health status and healthcare utilization in patients with somatoform disorders (SFD) of a specialized tertiary care center. Methods: According to DSM-IV interviews, 54 patients had somatization disorder (SD), 51 abridged somatization syndrome (SSI-8) and 67 other defined SFD. A clinical non-SFD comparison group consisted of 123 patients. Treatment effects were controlled against the waiting list. Cost calculations for the 2-year periods before and after treatment were based on medical and billing records from health insurance companies. Results: The SFD pat…

AdultMalemedicine.medical_specialtyCost effectivenessCost-Benefit AnalysisSampling StudiesSurveys and QuestionnairesmedicineHumansSomatization disorderProspective StudiesPsychiatrySomatoform DisordersAgedInpatient careCognitive Behavioral Therapybusiness.industryDepressionPublic healthCost-effectiveness analysisHealth ServicesMiddle Agedmedicine.diseaseMental healthDiagnostic and Statistical Manual of Mental DisordersPsychiatry and Mental healthClinical PsychologySocioeconomic FactorsPhysical therapyFemalebusinessPsychosocialSomatizationFollow-Up StudiesJournal of psychosomatic research
researchProduct

Indications and limitations of the fixator TGF “Gex-Fix” in proximal end humeral fractures

2014

Abstract The incidence of fractures of the humerus has increased exponentially in recent years. The most used classifications for humerus fracture are morphological (Neer), biological (AO/ASIF) and descriptive (Hertel). The types of surgical treatment for humerus fracture include prosthetic replacement and synthesis using different devices, including the Tension Guide Fixator (TGF), Gex-Fix. External fixation for displaced proximal humeral fractures avoids dissection and soft tissue stripping and has been reported by some authors to be associated with higher union rates, a lower incidence of avascular necrosis, less scarring of the scapulohumeral interface, and faster rehabilitation compare…

AdultMalemedicine.medical_specialtyExternal FixatorsCost-Benefit Analysismedicine.medical_treatmentHumerus fractureOsteoporosisHumeruAvascular necrosisExternal fixationFracture FixationSettore MED/33 - Malattie Apparato LocomotoremedicineHumansOutpatient clinicInternal fixationHumerusAgedGeneral Environmental ScienceAged 80 and overExternal fixatorbusiness.industryPatient SelectionSynthesiSoft tissueEquipment DesignMiddle Agedmedicine.diseaseTGFSurgeryTreatment OutcomeFracturemedicine.anatomical_structureHumeral HeadShoulder FracturesGeneral Earth and Planetary SciencesFemalebusinessLearning CurveBone WiresFollow-Up StudiesInjury
researchProduct

Oral high-dose sucrosomial iron vs intravenous iron in sideropenic anemia patients intolerant/refractory to iron sulfate: a multicentric randomized s…

2020

AbstractIron deficiency anemia is among the most frequent causes of disability. Intravenous iron is the quickest way to correct iron deficiency, bypassing the bottleneck of iron intestinal absorption, the only true mechanism of iron balance regulation in human body. Intravenous iron administration is suggested in patients who are refractory/intolerant to oral iron sulfate. However, the intravenous way of iron administration requires several precautions; as the in-hospital administration requires a resuscitation service, as imposed in Europe by the European Medicine Agency, it is very expensive and negatively affects patient’s perceived quality of life. A new oral iron formulation, Sucrosomi…

AdultMalemedicine.medical_specialtyResuscitationIntravenous sodium ferrigluconateAnemiaCost-Benefit AnalysisHigh dosesAdministration OralHigh dose030204 cardiovascular system & hematologyGastroenterologyFerric CompoundsIntestinal absorption03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRefractoryInternal medicineOral Sucrosomial ironMedicineHumans030212 general & internal medicineFerrous CompoundsProspective StudiesAgedAged 80 and overHematologyAnemia Iron-Deficiencybusiness.industryHematologyGeneral MedicineIron deficiencyMiddle Agedmedicine.diseaseIron sulfatechemistryIron-deficiency anemiaIron deficiency anemiaHematinicsAdministration IntravenousFemaleOriginal ArticleRefractoriness/intolerance to oral iron sulfatebusiness
researchProduct

Diagnostic Yield of 2 Strategies for Adult Celiac Disease Identification in Primary Care

2017

Goals: To compare the diagnostic yield and cost-consequences of 2 strategies, screening regardless of symptoms versus case finding (CF), using a point-of-care test (POCT), for the detection of celiac disease (CD) in primary care, to bridge the diagnostic gap of CD in adults. Materials and Methods: All subjects under 75 years of age who consecutively went to their general practitioners’ offices were offered POCT for anti-transglutaminase immunoglobulin A antibodies. The POCT was performed on all subjects who agreed, and then a systematic search for symptoms or conditions associated with higher risk for CD was performed, immediately after the test but before knowing the test results. The 2 …

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaAdolescentCross-sectional studyPoint-of-care testingCost-Benefit AnalysisPrimary careDisease03 medical and health sciencesprimary careYoung Adult0302 clinical medicinecase findingInternal medicineMedicineHumansMass Screening030212 general & internal medicineYoung adultMedical diagnosisAgedAged 80 and overdiseaseTransglutaminasesPrimary Health Carebusiness.industryscreeningGastroenterologyceliaMiddle AgedImmunoglobulin Acase finding; celiac disease; point-of-care test; primary care; screening; GastroenterologyCeliac DiseaseCross-Sectional StudiesPoint-of-Care TestingCase finding030211 gastroenterology & hepatologyObservational studypoint-of-care testFemalebusiness
researchProduct